189 related articles for article (PubMed ID: 22363762)
1. The prevalence and cost of unapproved uses of top-selling orphan drugs.
Kesselheim AS; Myers JA; Solomon DH; Winkelmayer WC; Levin R; Avorn J
PLoS One; 2012; 7(2):e31894. PubMed ID: 22363762
[TBL] [Abstract][Full Text] [Related]
2. Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.
Chua KP; Kimmel LE; Conti RM
Health Aff (Millwood); 2021 Mar; 40(3):453-460. PubMed ID: 33646878
[TBL] [Abstract][Full Text] [Related]
3. Beware the increasing cost and number of orphan drugs.
Silverman E
Manag Care; 2013 Mar; 22(3):10-4. PubMed ID: 23610800
[No Abstract] [Full Text] [Related]
4. Approved and investigational uses of modafinil : an evidence-based review.
Kumar R
Drugs; 2008; 68(13):1803-39. PubMed ID: 18729534
[TBL] [Abstract][Full Text] [Related]
5. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
6. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
7. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
8. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
9. Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kaura S
Health Aff (Millwood); 2016 Sep; 35(9):1588-94. PubMed ID: 27605637
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Orphan Drug Indications: 2010-2018.
Kimmel L; Conti RM; Volerman A; Chua KP
Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
12. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
13. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
14. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
Davies M; Wilton L; Shakir S
Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
[TBL] [Abstract][Full Text] [Related]
16. Investigating the landscape of US orphan product approvals.
Miller KL; Lanthier M
Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
Hong YD; Villalonga-Olives E; Perfetto EM
Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
[TBL] [Abstract][Full Text] [Related]
18. 2014 prescription medications in the United States: tremendous growth, specialty/orphan drug expansion, and dispensed prescriptions continue to increase.
Lindsley CW
ACS Chem Neurosci; 2015 Jun; 6(6):811-2. PubMed ID: 26081717
[No Abstract] [Full Text] [Related]
19. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
20. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.
Michaeli T; Michaeli DT
Value Health; 2024 Apr; 27(4):449-457. PubMed ID: 38244983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
